4-(1H-Pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine
CAS : 952518-97-7
Ref. 3D-CNB51897
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
Baricitinib is a drug that inhibits the activity of tyrosine kinase receptors, leading to inhibition of inflammatory cytokines. It is a potent inhibitor of IL-1β and TNF-α production in vitro. Baricitinib has been shown to inhibit the production of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α, by inhibiting the activity of inflammatory cells (e.g., macrophages). It also has anti-inflammatory effects on LPS-induced RAW 264.7 cells and assays. Baricitinib has been shown to inhibit cellular morphology changes induced by LPS stimulation and downregulate release of nitric oxide (NO) from stimulated cells in culture.